Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries

[1] Thiede M(1988)Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue Science 242 278-280

[2] Rodan GA(1995)Parathyroid hormone-related peptide as a locally produced vasorelaxant: regulation of its mRNA by hypertension in rats Biochem Biophys Res Commun 208 447-455

[3] Takahashi K(2010)Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT J Bone Miner Res 25 1941-1947

[4] Inoue D(2011)A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover J Bone Miner Res 26 2287-2297

[5] Ando K(2011)Intermittent PTH(1–84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites J Bone Miner Res 26 2583-2596

[6] Matsumoto T(2013)Vasodilation to PTH (1–84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling Bone 54 68-75

[7] Ikeda K(2000)Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893 J Bone Miner Res 15 1517-1525

[8] Fujita T(2012)Comparison of the skeletal effects induced by daily administration of PTHrP (1–36) and PTHrP (107–139) to ovariectomized mice J Cell Physiol 227 1752-1760

[9] Hansen S(2003)Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 88 569-575

[10] Beck Jensen JE(2008)Parathyroid hormone (1–84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy Calcif Tissue Int 83 85-92

[1] Thiede M(1988)Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue Science 242 278-280

[2] Rodan GA(1995)Parathyroid hormone-related peptide as a locally produced vasorelaxant: regulation of its mRNA by hypertension in rats Biochem Biophys Res Commun 208 447-455

[3] Takahashi K(2010)Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT J Bone Miner Res 25 1941-1947

[4] Inoue D(2011)A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover J Bone Miner Res 26 2287-2297

[5] Ando K(2011)Intermittent PTH(1–84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites J Bone Miner Res 26 2583-2596

[6] Matsumoto T(2013)Vasodilation to PTH (1–84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling Bone 54 68-75

[7] Ikeda K(2000)Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893 J Bone Miner Res 15 1517-1525

[8] Fujita T(2012)Comparison of the skeletal effects induced by daily administration of PTHrP (1–36) and PTHrP (107–139) to ovariectomized mice J Cell Physiol 227 1752-1760

[9] Hansen S(2003)Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 88 569-575

[10] Beck Jensen JE(2008)Parathyroid hormone (1–84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy Calcif Tissue Int 83 85-92